1.Regulatory role of nitric oxide on atrial natriuretic peptide system in normotensive and hypertensive rats.
Eun Hah CHOI ; Miwon KIM ; Jong Un LEE
The Korean Journal of Physiology and Pharmacology 1997;1(1):79-82
The present study was aimed to explore an interaction between endothelium-derived nitric oxide (NO) and atrial natriuretic peptide (ANP) systems in normotensive and hypertensive states. Rats were made two-kidney, one clip (2K1C) hypertensive and supplemented with either N-G-nitro-L-arginine methyl ester (L-NAME, 5 mg/100 ml drinking water) or L-arginine hydrochloride (400 mg/100 ml drinking water). One group supplied with normal tap water served as control. Sham-clipped rats were also divided into the L-NAME, L-arginine, and control groups. The plasma levels and atrial contents of ANP were determined at day 28 following clipping the renal artery. In 2K1C rats, the plasma level of ANP was higher and the atrial content was lower than in the sham-clipped control. L-Arginine increased the atrial content of ANP in association with a decreased plasma ANP, whereas L-NAME significantly affected neither parameter. The increase of blood pressure in 2K1C rats was not affected by L-arginine or L-NAME. In sham-clipped rats, the plasma level of ANP was significantly increased by L-NAME along with an increase in blood pressure. On the contrary, L-arginine did not affect the blood pressure or plasma ANP. The atrial content of ANP was significantly altered neither by L-arginine nor by L-NAME. These results suggest that NO plays a tonic inhibitory role on the ANP release with concomitant increases of the atrial tissue content. In addition, hypertension is suggested to modify the release and tissue storage of ANP.
Animals
;
Arginine
;
Atrial Natriuretic Factor
;
Blood Pressure
;
Drinking
;
Hypertension
;
NG-Nitroarginine Methyl Ester
;
Nitric Oxide*
;
Plasma
;
Rats*
;
Renal Artery
;
Water
2.Comparison of Pharmacological Treatments for Burning Mouth Syndrome.
Hyo Geun CHOI ; Eun Jung JUNG ; Won Yong LEE ; Heejin KIM ; Wonjae CHA ; J Hun HAH
Korean Journal of Otolaryngology - Head and Neck Surgery 2012;55(11):707-711
BACKGROUND AND OBJECTIVES: Burning mouth syndrome (BMS) refers to a collection of symptoms of patients who complain about burning sensation of their mouths without any specific causes. Although this is not a rare disease, the etiology and effective treatment are not well established. We tried to compare the efficacy and side effects of the agents that are reported to be relatively effective to BMS. SUBJECTS AND METHOD: Fifty-one patients who were diagnosed as BMS were chosen as candidates. Trazodone, Paroxetine, Clonazepam, and Gabapentin, which were known to be effective medicines for BMS in previous research were prescribed randomly. We prescribed medication for two weeks and evaluated patients for the effect and side effects at the end of the treatment. The medication was prescribed for 2 more weeks and the patients were evaluated again. RESULTS: Three of 11 (27.3%) patients were prescribed Trazodone, 8 of 12 (66.7%) Paroxetine, 8 of 14 (57.1%) Clonazepam and 12 of 14 (85.7%) Gabapentin. Q showed improvements after 4 weeks of medication. The differential effectiveness among the medications was not significant, except for the inferiority of Trazodone. Five of 11 (45.5%) patients who had been prescribed Trazodone, 2 of 12 (16.7%) who had been prescribed Paroxetine, 2 of 14 (14.3%) who had been prescribed Clonazepam, 2 of 14 (14.3%) who had been prescribed Gabapentin complained of side effects during 4 weeks of medication. CONCLUSION: We can expect high success rates of treatment for burning mouth syndrome with Paroxetine, Clonazepam and Gabapentin. A further study for long term outcomes and side effects in large groups is warranted.
Amines
;
Burning Mouth Syndrome
;
Burns
;
Clonazepam
;
Cyclohexanecarboxylic Acids
;
gamma-Aminobutyric Acid
;
Humans
;
Mouth
;
Paroxetine
;
Rare Diseases
;
Sensation
;
Trazodone
3.Kikuchi-Fujimoto disease mimicking malignant lymphoma with 2-18Ffluoro-2-deoxy-D-glucose PET/CT in children.
Ji Eun KIM ; Eun Kyung LEE ; Jae Min LEE ; Soon Hwan BAE ; Kwang Hae CHOI ; Young Hwan LEE ; Jeong Ok HAH ; Joon Hyuk CHOI ; Eun Jung KONG ; Ihn Ho CHO
Korean Journal of Pediatrics 2014;57(5):226-231
PURPOSE: Kikuchi-Fujimoto disease (KFD) is a benign disease, which is characterized by a cervical lymphadenopathy with fever, and it often mimics malignant lymphoma (ML). 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a powerful imaging modality for the diagnosis, staging and monitoring of ML, with the limitations including the nonspecific FDG uptake in infectious or inflammatory processes. This study compared clinical manifestations and PET/CT findings between KFD and ML patients. METHODS: We retrospectively reviewed the medical records of 23 patients with KFD and 33 patients with ML, diagnosed histopathologically, between January 2000 and May 2013 at the Department of Pediatrics, Yeungnam University Medical Center. Among them, we analyzed the clinical manifestations, laboratory findings and characteristics, and the amount of 18F-FDG uptake between 8 KFD and 9 ML patients who had 18F-FDG PET/CT. RESULTS: The 18F-FDG PET/CT maximum standardized uptake values (SUVmax) ranged from 8.3 to 22.5 (mean, 12.0) in KFDs, and from 5.8 to 34.3 (mean, 15.9) in MLs. There were no significant differences in SUVmax between KFDs and MLs. 18F-FDG PET/CT with ML patients showed hot uptakes in the extranodal organs, such as bone marrow, small bowel, thymus, kidney, orbit and pleura. However, none of the KFD cases showed extranodal uptake (P<0.001). 18F-FDG PET/CT findings of KFD with nodal involvement only were indistinguishable from those of ML. CONCLUSION: Patients who had extranodal involvement on PET/CT were more likely to have malignancy than KFD.
Academic Medical Centers
;
Bone Marrow
;
Child*
;
Diagnosis
;
Electrons
;
Fever
;
Fluorodeoxyglucose F18
;
Histiocytic Necrotizing Lymphadenitis*
;
Humans
;
Kidney
;
Lymphatic Diseases
;
Lymphoma*
;
Medical Records
;
Orbit
;
Pediatrics
;
Pleura
;
Positron-Emission Tomography
;
Positron-Emission Tomography and Computed Tomography*
;
Retrospective Studies
;
Thymus Gland
4.Human salivary gland stem cells ameliorate hyposalivation of radiation-damaged rat salivary glands.
Jaemin JEONG ; Hyunjung BAEK ; Yoon Ju KIM ; Youngwook CHOI ; Heekyung LEE ; Eunju LEE ; Eun Sook KIM ; Jeong Hun HAH ; Tack Kyun KWON ; Ik Joon CHOI ; Heechung KWON
Experimental & Molecular Medicine 2013;45(11):e58-
Salivary function in mammals may be defective for various reasons, such as aging, Sjogren's syndrome or radiation therapy in head and neck cancer patients. Recently, tissue-specific stem cell therapy has attracted public attention as a next-generation therapeutic reagent. In the present study, we isolated tissue-specific stem cells from the human submandibular salivary gland (hSGSCs). To efficiently isolate and amplify hSGSCs in large amounts, we developed a culture system (lasting 4-5 weeks) without any selection. After five passages, we obtained adherent cells that expressed mesenchymal stem cell surface antigen markers, such as CD44, CD49f, CD90 and CD105, but not the hematopoietic stem cell markers, CD34 and CD45, and that were able to undergo adipogenic, osteogenic and chondrogenic differentiation. In addition, hSGSCs were differentiated into amylase-expressing cells by using a two-step differentiation method. Transplantation of hSGSCs to radiation-damaged rat salivary glands rescued hyposalivation and body weight loss, restored acinar and duct cell structure, and decreased the amount of apoptotic cells. These data suggest that the isolated hSGSCs, which may have characteristics of mesenchymal-like stem cells, could be used as a cell therapy agent for the damaged salivary gland.
Amylases/genetics/metabolism
;
Animals
;
Antigens, CD/genetics/metabolism
;
Apoptosis
;
Cell Differentiation
;
Humans
;
Male
;
Mesenchymal Stromal Cells/*cytology/metabolism
;
Radiation Injuries, Experimental
;
Rats
;
Rats, Wistar
;
*Regeneration
;
Salivary Glands/cytology/injuries/physiology/*surgery
;
*Salivation
;
*Stem Cell Transplantation
5.Novel influenza A (H1N1) 2009 infection in the pediatric patients with hematologic and oncologic diseases in the Yeungnam region.
Seok Jeong KANG ; Jae Min LEE ; Jeong Ok HAH ; Ye Jee SHIM ; Kun Soo LEE ; Hyun Jung SHIN ; Heung Sik KIM ; Eun Jin CHOI ; So Eun JEON ; Young Tak LIM ; Ji Kyeong PARK ; Eun Sil PARK
Korean Journal of Pediatrics 2011;54(3):117-122
PURPOSE: Natural history and consequences of the novel 2009 influenza A H1N1 (2009 H1N1) infection in immunocompromised pediatric patients are not yet fully understood. In this study, we investigated the clinical features and outcomes of the 2009 H1N1 infection in pediatric patients with hematological and oncological diseases. METHODS: We retrospectively reviewed the medical records of 528 patients who had hematological and oncological diseases and who were treated at 7 referral centers located in the Yeungnam region. Among the 528 patients, 27 with definite diagnosis of 2009 H1N1 infection were the subjects of this study. All patients were divided into the following 3 groups: patients who were receiving chemotherapy (group 1), patients who were immunosuppressed due to a non-malignant hematological disease (group 2), and patients who were off chemotherapy and had undergone their last chemotherapy course within 2 years from the influenza A pandemic (group 3). RESULTS: All 28 episodes of 2009 H1N1 infection were treated with the antiviral agent oseltamivir (Tamiflu(R)), and 20 episodes were treated after hospitalization. Group 1 patients had higher frequencies of lower respiratory tract infection and longer durations of fever and hospitalization as compared to those in group 2. Ultimately, all episodes resolved completely with no complications. CONCLUSION: These results suggest that early antiviral therapy did not influence the morbidity or mortality of pediatric patients with hematological and oncological diseases in the Yeungnam region of Korea after the 2009 H1N1 infection. However, no definite conclusions can be drawn because of the small sample size.
Child
;
Fever
;
Hematologic Diseases
;
Hospitalization
;
Humans
;
Immunocompromised Host
;
Influenza A virus
;
Influenza, Human
;
Korea
;
Medical Records
;
Natural History
;
Oseltamivir
;
Pandemics
;
Referral and Consultation
;
Respiratory Tract Infections
;
Retrospective Studies
;
Sample Size
6.Overexpression of Neuron-Specific Enolase as a Prognostic Factor in Patients with Gastric Cancer.
Taejin PARK ; Young Joon LEE ; Sang Ho JEONG ; Sang Kyung CHOI ; Eun Jung JUNG ; Young tae JU ; Chi Young JEONG ; Miyeong PARK ; Young Sool HAH ; Jiyun YOO ; Woo Song HA ; Soon Chan HONG ; Gyung Hyuck KO
Journal of Gastric Cancer 2017;17(3):228-236
PURPOSE: Enolase is a cytoplasmic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate in the glycolytic pathway. The aim of this study was to investigate whether the overexpression of neuron-specific enolase (NSE) can serve as a prognostic factor in patients with gastric cancer (GC). MATERIALS AND METHODS: To assess its prognostic value in GC, NSE expression was measured by immunohistochemistry in a clinically annotated tissue microarray comprising of 327 human GC specimens. Cytoplasmic NSE expression was scored from 0 to 4, reflecting the percentage of NSE-positive cells. RESULTS: In terms of histology as per the World Health Organization criteria (P=0.340), there were no differences between the NSE overexpression (NSE-OE) and NSE underexpression (NSE-UE) groups. The NSE-OE group showed a significantly lower rate of advanced GC (P<0.010), lymph node metastasis (P=0.010), advanced stage group (P<0.010), cancer-related death (P<0.010), and cancer recurrence (P<0.010). Additionally, a Kaplan-Meier survival analysis revealed that the NSE-OE group had longer cumulative survival times than the NSE-UE group (log-rank test, P<0.010). However, there were no significant differences in the serum levels of NSE expression in patients with GC and healthy volunteers (P=0.280). CONCLUSIONS: Patients with NSE overexpressing GC tissues showed better prognostic results, implying that NSE could be a candidate biomarker of GC.
Cytoplasm
;
Healthy Volunteers
;
Humans
;
Immunohistochemistry
;
Lymph Nodes
;
Neoplasm Metastasis
;
Phosphoenolpyruvate
;
Phosphopyruvate Hydratase*
;
Prognosis
;
Recurrence
;
Stomach Neoplasms*
;
World Health Organization
7.Clinical characteristics and treatment courses for cytomegalovirus-associated thrombocytopenia in immunocompetent children after neonatal period.
Min Ji JIN ; Yunkyum KIM ; Eun Mi CHOI ; Ye Jee SHIM ; Heung Sik KIM ; Jin Kyung SUH ; Ji Yoon KIM ; Kun Soo LEE ; Sun Young PARK ; Jae Min LEE ; Jeong Ok HAH
Blood Research 2018;53(2):110-116
BACKGROUND: Cytomegalovirus (CMV) causes severe diseases in premature infants and immunocompromised hosts, and antiviral therapy is often required for disease control. However, the clinical manifestations and treatment courses for CMV-associated thrombocytopenia in immunocompetent children are unclear. METHODS: Medical records of the children who suffered from thrombocytopenia, and showed positive CMV polymerase chain reaction and CMV-like symptoms were retrospectively analyzed at three university hospitals in Daegu from January 2000 to March 2017. Patients suffering from leukemia, immunodeficiency, and other infections were excluded. RESULTS: Among 1,065 children with thrombocytopenia, 29 (2.7%) displayed CMV-associated thrombocytopenia. The median age at diagnosis was 15 months and the median platelet count was 26,000/µL. They were classified into the CMV-induced thrombocytopenia (23/29) and CMV-related secondary immune thrombocytopenia (ITP, 6/29) groups. Fourteen subjects had hepatic dysfunction, four had Evans syndrome, two had pneumonitis, and one had gastritis. IVIG was used for 21 patients, and six patients among them showed recurrence, for whom IVIG or antiviral therapy was used. All, except one, recurrent or chronic cases belonged to the CMV-induced thrombocytopenia group. Antiviral therapy was used more frequently for the CMV-induced thrombocytopenia group (8/23, 34.8%) than for the CMV-related secondary ITP group (0/6); however, the results were not statistically significant (P=0.148). CONCLUSION: CMV is a rare but unique etiology of thrombocytopenia, and observed even in healthy children after the neonatal period. About one-third patients need antiviral therapy for disease control. Further, CMV-induced thrombocytopenia is more complex than CMV-related secondary ITP.
Child*
;
Cytomegalovirus
;
Daegu
;
Diagnosis
;
Ganciclovir
;
Gastritis
;
Hospitals, University
;
Humans
;
Immunocompromised Host
;
Immunoglobulins, Intravenous
;
Infant, Newborn
;
Infant, Premature
;
Leukemia
;
Medical Records
;
Platelet Count
;
Pneumonia
;
Polymerase Chain Reaction
;
Purpura, Thrombocytopenic, Idiopathic
;
Recurrence
;
Retrospective Studies
;
Thrombocytopenia*
8.Epidemiological Study of Hereditary Hemolytic Anemia in the Korean Pediatric Population during 1997–2016: a Nationwide Retrospective Cohort Study
Ye Jee SHIM ; Hye Lim JUNG ; Hee Young SHIN ; Hyoung Jin KANG ; Jung Yoon CHOI ; Jeong Ok HAH ; Jae Min LEE ; Young Tak LIM ; Eu Jeen YANG ; Hee Jo BAEK ; Hyoung Soo CHOI ; Keon Hee YOO ; Jun Eun PARK ; Seongkoo KIM ; Ji Yoon KIM ; Eun Sil PARK ; Ho Joon IM ; Hee Won CHUEH ; Soon Ki KIM ; Jae Hee LEE ; Eun Sun YOO ; Hyeon Jin PARK ; Jun Ah LEE ; Meerim PARK ; Hyun Sik KANG ; Ji Kyoung PARK ; Na Hee LEE ; Sang Kyu PARK ; Young-Ho LEE ; Seong Wook LEE ; Eun Jin CHOI ; Seom Gim KONG
Journal of Korean Medical Science 2020;35(33):e279-
Background:
Hereditary hemolytic anemia (HHA) is a rare disease characterized by premature red blood cell (RBC) destruction due to intrinsic RBC defects. The RBC Disorder Working Party of the Korean Society of Hematology established and updated the standard operating procedure for making an accurate diagnosis of HHA since 2007. The aim of this study was to investigate a nationwide epidemiology of Korean HHA.
Methods:
We collected the data of a newly diagnosed pediatric HHA cohort (2007–2016) and compared this cohort's characteristics with those of a previously surveyed pediatric HHA cohort (1997–2006) in Korea. Each participant's information was retrospectively collected by a questionnaire survey.
Results:
A total of 369 children with HHA from 38 hospitals distributed in 16 of 17 districts of Korea were investigated. RBC membranopathies, hemoglobinopathies, RBC enzymopathies, and unknown etiologies accounted for 263 (71.3%), 59 (16.0%), 23 (6.2%), and 24 (6.5%) of the cases, respectively. Compared to the cohort from the previous decade, the proportions of hemoglobinopathies and RBC enzymopathies significantly increased (P < 0.001 and P = 0.008, respectively). Twenty-three of the 59 hemoglobinopathy patients had immigrant mothers, mostly from South-East Asia.
Conclusion
In Korea, thalassemia traits have increased over the past 10 years, reflecting both increased awareness of this disease and increased international marriages. The enhanced recognition of RBC enzymopathies is due to advances in diagnostic technique; however, 6.5% of HHA patients still do not have a clear diagnosis. It is necessary to improve accessibility of diagnosing HHA.
9.Autologous Stem Cell Transplantation for the Treatment of Neuroblastoma in Korea.
Kyung Ha RYU ; Hyo Seop AHN ; Hong Hoe KOO ; Hoon KOOK ; Moon Kyu KIM ; Hack Ki KIM ; Thad GHIM ; Hyung Nam MOON ; Jong Jin SEO ; Ki Woong SUNG ; Hee Young SHIN ; Eun Sun YOO ; Chuhl Joo LYU ; Young Ho LEE ; Hahng LEE ; Bin CHO ; Hyun Sang CHO ; Hyung Soo CHOI ; Jeong Ok HAH ; Tai Ju HWANG
Journal of Korean Medical Science 2003;18(2):242-247
Autologous stem cell transplantation (ASCT) for the treatment of high-risk neuroblastoma (NBL) is an accepted method for restoring bone marrow depression after high dose chemotherapy. We retrospectively analyzed eighty eight cases of NBL that underwent ASCT following marrow ablative therapy at 12 transplant centers of the Korean Society of Pediatric Hematology-Oncology between January 1996 and September 2000. Seventy nine children were of stage IV NBL and 9 were of stage III with N-myc amplification. Various cytoreductive regimens were used. However, the main regimen was 'CEM' consisting of carboplatin, etoposide and melphalan, and this was used in 66 patients. Total body irradiation was also added in 36 patients for myeloablation. To reduce tumor cell contamination, stem cell infusions after CD34+ cell selection were performed in 16 patients. Post-transplantation therapies included the second transplantation in 18 patients, interleukin2 therapy in 45, 13-cis retinoic acid in 40, 131-meta-iodobenzylguanidine in 4, conventional chemotherapy in 11, and local radiotherapy in 8. Twenty two patients died, sixty six patients are surviving 1 to 46 months after ASCT (median followup duration, 14.5 months). Although the follow-up period was short and the number of patients small, we believe that ASCT might improve the survival rate in high-risk NBL.
Adolescent
;
Child
;
Child, Preschool
;
Combined Modality Therapy
;
Female
;
Human
;
Korea
;
Male
;
Myeloablative Agonists/therapeutic use
;
Neuroblastoma/mortality
;
Neuroblastoma/pathology
;
Neuroblastoma/therapy*
;
Retrospective Studies
;
Stem Cell Transplantation*
;
Survival Rate
;
Transplantation Conditioning
;
Transplantation, Autologous
;
Treatment Outcome
10.Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro).
Jae Hoon MOON ; Ji hoon KIM ; Eun Kyung LEE ; Kyu Eun LEE ; Sung Hye KONG ; Yeo Koon KIM ; Woo jin JUNG ; Chang Yoon LEE ; Roh Eul YOO ; Yul HWANGBO ; Young Shin SONG ; Min Joo KIM ; Sun Wook CHO ; Su jin KIM ; Eun Jae JUNG ; June Young CHOI ; Chang Hwan RYU ; You Jin LEE ; Jeong Hun HAH ; Yuh Seog JUNG ; Junsun RYU ; Yunji HWANG ; Sue K PARK ; Ho Kyung SUNG ; Ka Hee YI ; Do Joon PARK ; Young Joo PARK
Endocrinology and Metabolism 2018;33(2):278-286
BACKGROUND: The ongoing Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro) aims to observe the natural course of papillary thyroid microcarcinoma (PTMC), develop a protocol for active surveillance (AS), and compare the long-term prognosis, quality of life, and medical costs between the AS and immediate surgery groups. METHODS: This multicenter prospective cohort study of PTMC started in June 2016. The inclusion criteria were suspicious of malignancy or malignancy based on fine needle aspiration or core needle biopsy, age of ≥18 years, and a maximum diameter of ≤1 cm. If there was no major organ involvement, no lymph node/distant metastasis, and no variants with poor prognosis, the patients were explained of the pros and cons of immediate surgery and AS before selecting AS or immediate surgery. Follow-up visits (physical examination, ultrasonography, thyroid function, and questionnaires) are scheduled every 6 months during the first 2 years, and then every 1 year thereafter. Progression was defined as a maximum diameter increase of ≥3, ≥2 mm in two dimensions, suspected organ involvement, or lymph node/distant metastasis. RESULTS: Among 439 enrolled patients, 290 patients (66.1%) chose AS and 149 patients (33.9%) chose immediate surgery. The median follow-up was 6.7 months (range, 0.2 to 11.9). The immediate surgery group had a larger maximum tumor diameter, compared to the AS group (7.1±1.9 mm vs. 6.6±2.0 mm, respectively; P=0.014). CONCLUSION: The results will be useful for developing an appropriate PTMC treatment policy based on its natural course and risk factors for progression.
Biopsy, Fine-Needle
;
Biopsy, Large-Core Needle
;
Cohort Studies*
;
Follow-Up Studies
;
Humans
;
Neoplasm Metastasis
;
Prognosis
;
Prospective Studies*
;
Quality of Life
;
Risk Factors
;
Thyroid Gland*
;
Thyroid Neoplasms
;
Ultrasonography